Page 1

Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 30 JUNE 2026 CLEVER CULTURE SYSTEMS Adelaide , Australia , 30 July 2026 : Australian medical technology company Clever Culture Systems Ltd ( ASX : CC5 ) ( CCS or the Company ) , a leader in microbiology automation using artificial intelligence , is pleased to release its Appendix 4C - Quarterly Cashflow report and business update for the quarter ended 30 June 2026 ( the Quarter ) . All financial results are in Australian dollars and are unaudited . Key Highlights • • • • FY26 delivers expanded global customer base : APAS® Independence has now been placed with eight large global pharmaceutical companies , double the number compared to FY25 , in addition to other new pharmaceutical customers and established clinical laboratory customers Existing customers underpin growth potential : FY26 sales strategy to add new global pharmaceutical customers establishes a solid base of existing customer relationships for expected sales growth FY27 sales expectations strengthened : existing customers to gain momentum and underpin sales , supplemented by additional qualified customer sales opportunities Pipeline : The Company's eight large global pharmaceutical customers alone represent an estimated medium - term opportunity of up to 100 instrument sales . This is in addition to approximately 80 instrument opportunities across new qualified pharmaceutical customer pipeline • Annual Recurring Revenue growth : high - margin predominantly software licenses exceeds $ 1.3m p.a. Cash : 30 June 2026 cash balance of $ 1.7 million , and $ 3.4 million in known / committed cash inflows expected over the next two quarters Regarding the Quarter , Brent Barnes , CEO and Managing Director said : " FY26 saw an effective ' Land ' campaign , doubling the number of large global pharmaceutical manufacturers with APAS® Independence . The growth in our customer base represents a significant direct opportunity , as we now look to expand APAS® deployments across these customer organisations over the coming 12 months . Our additional new qualified customer sales opportunities further underpin expectations of sales growth opportunities . We are excited to be moving into the sales expansion phase starting in FY27 and beyond . " Sales delivery and execution Sales Progress Summary – Land & Expand in pharmaceutical market continues to build momentum Large Global Pharmaceutical Customers¹ Instruments Installed Base² New Orders Received in the Quarter³ Q4 FY26 8 34 3 3 Q3 FY26 6 332 30 Q4 FY25 4 24 1 1 Instruments under evaluation APAS® Independence placements with two new large global pharmaceutical customers The Company completed installations with two new large global pharmaceutical customers . In June , Australian medical technology leader CSL Behring ( CSL ) placed a 5 - year lease order for an APAS® Independence instrument . The instrument 1 Refers to the largest top - 30 global pharmaceutical customers based on their annual reported revenues 2 APAS® instruments have been fully purchased and installed ( Pharma & Clinical ) , excludes instruments under evaluation with a return option 3 All orders received and committed within the Quarter ( Pharma & Clinical ) , including orders received by Thermo Fisher . Instruments may not be installed . Page 1 of 4